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Reduced Expression of Connective Tissue Growth
Factor (CTGF/CCN2) Mediates Collagen Loss in
Chronologically Aged Human Skin
TaiHao Quan1, Yuan Shao1, Tianyuan He1, John J. Voorhees1 and Gary J. Fisher1
Reduced production of type I procollagen is a prominent feature of chronologically aged human skin.
Connective tissue growth factor (CTGF/CCN2), a downstream target of the transforming growth factor-b
(TGF-b)/Smad pathway, is highly expressed in numerous fibrotic disorders, in which it is believed to stimulate
excessive collagen production. CTGF is constitutively expressed in normal human dermis in vivo, suggesting
that CTGF is a physiological regulator of collagen expression. We report here that the TGF-b/Smad/CTGF axis is
significantly reduced in dermal fibroblasts, the major collagen-producing cells, in aged (X80 years) human skin
in vivo. In primary human skin fibroblasts, neutralization of endogenous TGF-b or knockdown of CTGF
substantially reduced the expression of type I procollagen mRNA, protein, and promoter activity. In contrast,
overexpression of CTGF stimulated type I procollagen expression, and increased promoter activity. Inhibition of
TGF-b receptor kinase, knockdown of Smad4, or overexpression of inhibitory Smad7 abolished CTGF
stimulation of type I procollagen expression. However, CTGF did not stimulate Smad3 phosphorylation or
Smad3-dependent transcriptional activity. These data indicate that in human skin fibroblasts, type I procollagen
expression is dependent on endogenous production of both TGF-b and CTGF, which act through
interdependent yet distinct mechanisms. Downregulation of the TGF-b/Smad/CTGF axis likely mediates
reduced type I procollagen expression in aged human skin in vivo.
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INTRODUCTION
Connective tissue growth factor (CTGF/CCN2) is a member of
the CCN (CCN1-6) family of cystein-rich, matricellular
secreted proteins. CTGF exhibits diverse biological activities
in vitro, such as cell proliferation, adhesion, migration, and
extracellular matrix (ECM) production (Grotendorst, 1997;
Babic et al., 1999; Brigstock, 1999; Duncan et al., 1999;
Gupta et al., 2000; Chen et al., 2001a). CTGF is primarily
induced by transforming growth factor-b (TGF-b) in human
skin fibroblasts (Quan et al., 2002b) and seems to function as
a downstream mediator of TGF-b’s ability to stimulate ECM
synthesis. CTGF stimulates collagen synthesis when injected
into mouse skin or added to cultured renal fibroblasts
(Duncan et al., 1999). Several lines of evidence indicate that
CTGF is markedly elevated in numerous fibrotic disorders,
involving the skin, lungs, and kidneys, in which it is believed
to stimulate excessive deposition of collagen. Recently,
Ivkovic et al. (2003) developed CTGF-null mice, which die
shortly after birth, primarily due to respiratory failure caused
by skeletal defects, indicating that CTGF plays a crucial role
in the regulation of cartilage ECM production during
development.
Although the role of CTGF in fibrotic disorders has
received considerable attention, the role of CTGF in
physiological regulation of type I procollagen expression in
normal human skin has received less attention (Shi-Wen
et al., 2008). CTGF was shown to be expressed in fibrotic skin
diseases such as scleroderma (Bradham et al., 1991; Frazier
et al., 1996; Grotendorst et al., 1996; Grotendorst, 1997;
Abraham et al., 2000). CTGF is also constitutively expressed,
and readily detectable, in normal adult human skin in vivo
and normal human skin fibroblasts (Quan et al., 2002b).
In contrast to fibrotic disease, chronologically aged human
skin displays reduced production of type I procollagen, the
major structural protein in human skin connective tissue. This
loss of dermal collagen significantly contributes to increased
skin fragility and impaired wound healing in aged human
skin. Underlying mechanisms responsible for reduced col-
lagen biosynthesis in chronologically aged human skin are
largely unknown.
We report here that TGF-b1, CTGF, and type I procollagen
are significantly downregulated in fibroblasts in aged human
skin compared with those in young human skin in vivo. In
See related commentary on pg 338
& 2010 The Society for Investigative Dermatology www.jidonline.org 415
ORIGINAL ARTICLE
Received 9 December 2008; revised 22 May 2009; accepted 11 June 2009;
published online 30 July 2009
1Department of Dermatology, University of Michigan, Ann Arbor, Michigan,
USA
Correspondence: Dr Gary J. Fisher, Department of Dermatology, University of
Michigan Medical School, 1150 W. Medical Center Drive, Medical Science I,
Room 6447, Ann Arbor, Michigan 48109-5609, USA.
E-mail: dianemch@umich.edu
Abbreviations: CTGF, connective tissue growth factor; ECM, extracellular
matrix; JNK, c-Jun NH2-terminal kinase; MAPK, mitogen-activated protein
kinase; TGF-b, transforming growth factor-b
primary human skin fibroblasts, TGF-b and CTGF act in
concert, through interdependent yet distinct mechanisms, to
regulate type I procollagen production. These data support
the conclusion that TGF-b/Smad/CTGF forms an axis that
regulates collagen production in human skin fibroblasts, and
that attenuation of this axis contributes to reduced collagen
content observed in aged human skin.
RESULTS
TGF-b1, CTGF, and type I procollagen expression in dermal
fibroblasts are reduced in aged human skin in vivo
Adult human dermis expresses transcripts for TGF-b1, b2, and
b3 in a ratio of 1:0.6:0.4. Levels of TGF-b2 or TGF-b3
transcripts, in the dermis of young (21–30 years) compared
with that in aged (X80 years) individuals did not significantly
differ (n¼6, data not shown). In contrast, TGF-b1 mRNA
levels were significantly reduced (70%) in aged compared
with those in young individuals (Figure 1a). Localization of
TGF-b1 mRNA and protein, in the dermis of young and aged
individuals, was determined by in situ hybridization and
immunohistology, respectively. TGF-b1 mRNA (Figure 1b) and
protein (Figure 1c) were expressed primarily in vascular cells
and interstitial fibroblasts in the upper dermis in young skin.
TGF-b1 protein was primarily localized in the ECM, consistent
with its known secretion and binding to ECM components. In
aged skin, TGF-b1 mRNA (Figure 1b) and protein (Figure 1c)
expressions, in the dermis, were markedly reduced compared
with those in young skin. Laser capture microdissection was
used to obtain fibroblasts from young and aged skin. TGF-b1
mRNA in captured fibroblasts was quantified by real-time
reverse transcriptase PCR. TGF-b1 gene expression in fibro-
blasts in aged skin was reduced by 87% compared with that in
fibroblasts in young skin (Figure 1d).
The CTGF gene expression is directly regulated by TGF-b-
activated Smad proteins, and TGF-b and CTGF are often
overexpressed in fibrotic diseases. Therefore, we examined
CTGF expression in young and aged human skin dermis. We
found that basal expression of CTGF mRNA (Figure 2a)
was approximately 200 times higher than that of TGF-b
(Figure 1a), based on relative copy number. CTGF mRNA
was substantially reduced (50%) in aged dermis compared
with that in young dermis (Figure 2a). CTGF mRNA
(Figure 2b) and protein (Figure 2c), similar to TGF-b1, were
expressed in vascular cells and interstitial fibroblasts in young
skin dermis. In aged dermis, expression of CTGF mRNA
(Figure 2b) and protein (Figure 2c) was substantially reduced
compared with that in young dermis. CTGF immunostaining
was primarily localized in cells. Secreted CTGF, which binds
to the ECM, was not detected with the antibody that was
used. Fibroblasts from young and aged skin were obtained by
laser capture microdissection. CTGF mRNA levels were
approximately 57% lower in fibroblasts in aged dermis com-
pared with those in fibroblasts in young dermis (Figure 2d).
Given that TGF-b and CTGF are important mediators of
fibrosis, their reduced expression in aged dermis could lower
the levels of collagen production. To examine this possi-
bility, mRNA and protein expression of type I procollagen,
the major structural component of the dermal ECM, were
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Figure 1. TGF-b1 mRNA and protein expression are reduced in the dermis of
aged human skin in vivo. (a) Total RNA was prepared from dermis obtained
by dissection of full-thickness young (21–30 years) or aged (X80 years)
human skin. TGF-b1 and 36B4 (internal reference for normalization) mRNA
were quantified in the dermis of young (21–30 years) and aged (X80 years)
human skin, by real-time reverse transcriptase (RT)-PCR. Data are
means±SEM, N¼ 6 young and 6 aged individuals, *Po0.05. (b) Localization
of TGF-b1 mRNA in the dermis of young and aged human skin was
determined by antisense riboprobe in situ hybridization. Open arrows
indicate vascular cell. Solid arrows indicate fibroblasts. Results are
representative of five young and five aged individuals. Bar¼ 300mm.
(c) Localization of TGF-b1 protein, in the dermis of young and aged human
skin, was determined by immunohistology. Results are representative of five
young and five aged individuals. Bar¼ 300mm. (d) Dermal fibroblasts were
obtained by laser capture microdissection from frozen sections of young
(21–30 years) and aged (X80 years) human skin. TGF-b1 and 36B4 (internal
reference) mRNA levels were quantified by real-time RT-PCR. Data are
means±SEM, N¼ 6 young and 6 aged individuals, *Po0.05.
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determined in young and aged human skin dermis. Type I
procollagen mRNA levels in aged dermis were significantly
lower than those in young dermis (Figure 3a). Type I
procollagen mRNA (Figure 3b) and protein (Figure 3c) were
readily detected in fibroblasts in young skin dermis.
Fibroblast expression of both type I procollagen mRNA
(Figure 3b) and protein (Figure 3c) were strikingly reduced in
aged dermis. Type I procollagen gene expression was
reduced by approximately 75% in fibroblasts, obtained by
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Figure 2. CTGF mRNA and protein expression are reduced in the dermis of
aged human skin in vivo. (a) Total RNA was prepared from the dermis,
obtained by dissection of full-thickness young (21–30 years) and aged (80 or
greater years of age) human skin. CTGF and 36B4 (internal reference for
normalization) mRNA levels were quantified by real-time reverse
transcriptase (RT)-PCR. Data are means±SEM, N¼ 5 young and 5 aged
individuals, *Po0.05. (b) Localization of CTGF mRNA in the dermis of young
and aged human skin was determined by antisense riboprobe in situ
hybridization. Results are representative of five young and five aged
individuals. Bar¼ 300mm. Open arrows indicate vascular cell. Solid arrows
indicate fibroblasts. (c) Localization of CTGF protein, in the dermis of young
and aged human skin, was determined by immunohistology. Results are
representative of five young and five aged individuals. Bar¼ 300mm.
(d) Dermal fibroblasts were obtained by laser capture microdissection from
frozen sections of young (21–30 years) and aged (X80 years) human skin.
CTGF and 36B4 (internal reference for normalization) mRNA levels were
quantified by real-time RT-PCR. Data are means±SEM, N¼ 8 young and
8 aged individuals, *Po0.05.
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Figure 3. Type I procollagen mRNA and protein expression are reduced in
the dermis of aged human skin in vivo. (a) Total RNA was prepared from the
dermis obtained by dissection of full-thickness young (21–30 years) and aged
(X80 years) human skin. Type I procollagen and 36B4 (internal reference)
mRNA levels were quantified by real-time reverse transcriptase (RT)-PCR.
Data are means±SEM, N¼6 young and 6 aged individuals, *Po0.05.
(b) Localization of type I procollagen mRNA, in the dermis of young and aged
human skin, was determined by antisense riboprobe in situ hybridization.
Results are representative of five young and five aged individuals.
Bar¼300 mm. (c) Localization of type I procollagen protein, in the dermis of
young and aged human skin, was determined by immunohistology. Results
are representative of five young and five aged individuals. Bar¼ 300mm.
(d) Dermal fibroblasts were obtained by laser capture microdissection from
frozen sections of young (21–30 years) and aged (X80 years) human skin.
Type I procollagen and 36B4 (internal reference for normalization) mRNA
levels were quantified by real-time RT-PCR. Data are means±SEM, N¼13
young and 13 aged individuals, *Po0.05.
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laser capture microdissection, in aged dermis compared with
that in fibroblasts in young dermis (Figure 3d).
Autocrine TGF-b stimulates CTGF and type I procollagen
expression in human dermal fibroblasts
Given the compelling evidence that increased TGF-b and
CTGF contribute to overproduction of collagen in fibrotic
diseases, the above data suggest that reduced TGF-b and
CTGF may contribute to physiological, age-related reduction
of type I collagen production in human skin. To examine this
possibility, we used primary human skin dermal fibroblasts to
investigate functional relationships among TGF-b, CTGF, and
type I procollagen expression. Human dermal fibroblasts
express all three isoforms of TGF-b: TGF-b1, TGF-b2, and
TGF-b3 (data not shown). Treatment of fibroblast cultures
with pan-TGF-b-neutralizing antibody significantly reduced
expression of CTGF and type I procollagen. CTGF mRNA
expression was reduced by approximately 75% (Figure 4a);
type I procollagen mRNA (Figure 4b) and protein (Figure 4c)
were reduced by approximately 80%.
To confirm the importance of autocrine TGF-b in the
regulation of CTGF and type I procollagen, we reduced the
endogenous expression of TGF-b1, TGF-b2, and TGF-b3 with
siRNA. Each TGF-b isoform was reduced by approximately
60% (Figure 5a). Knockdown of each TGF-b isoform
separately reduced CTGF and type I procollagen by
20–30% (data not shown). In combination, knockdown of
TGF-b1, TGF-b2, and TGF-b3 yielded approximately 60%
reduction of CTGF mRNA (Figure 5b) and protein (Figure 5c),
confirming that basal expression of CTGF is substantially
dependent on fibroblast production of TGF-b. Human dermal
fibroblasts expressed primarily 38- and 35-kDa forms of
CTGF, although other small CTGF fragments were also
detected. TGF-b1/2/3 knockdown reduced type I procollagen
mRNA (Figure 5d) and protein (Figure 5e) by 70%.
The TGF-b acts primarily through its cell surface receptor
complex composed of type I (ALK5), type II, and type III
(betaglycan) receptors. We used a specific TGF-b type I
receptor kinase inhibitor SB431542 (Laping et al., 2002;
Halder et al., 2005), which, we have confirmed, effectively
blocks TGF-b-induced Smad2 phosphorylation and TGF-b-
induced Smad-dependent reporter gene activity in human
skin fibroblasts (data not shown) to investigate TGF-b
receptor-dependence of CTGF and type I procollagen
expression by autocrine TGF-b. Treatment of fibroblasts with
SB431542 reduced CTGF mRNA (Figure 6a) and protein
(Figure 6b) levels by approximately 90%. Type I procollagen
mRNA (Figure 6c) and protein (Figure 6d) expressions were
also decreased by approximately 90% in fibroblasts treated
with SB431542.
Knockdown of CTGF reduces expression of type I procollagen
in human skin fibroblasts
Taken together, the above data show that autocrine TGF-b is
the major mediator of CTGF and type I procollagen
production in primary human dermal fibroblasts. To explore
the extent to which CTGF is involved in autocrine TGF-b
stimulation of type I procollagen production, we used
siRNA-mediated knockdown. CTGF mRNA (Figure 7a) and
protein (Figure 7b) levels were reduced by 71 and 78%,
respectively, 3 days after transfection of CTGF siRNA, and
remained at this minimum level for at least 5 days (data not
shown). Knockdown of CTGF had no effect on the mRNA
levels of any of the other five CCN family members (data not
shown), indicating that the effect of the CTGF siRNA was
specific (and the levels of other CCN family members are not
dependent on CTGF). In addition, CTGF knockdown did not
alter the expression of TGF-b1/2/3 (data not shown). At 3 days
after the transfection of CTGF siRNA, type I procollagen
mRNA (Figure 7c) and protein (Figure 7d) were reduced by
55 and 65%, respectively. These data indicate that CTGF
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Figure 4. Neutralization of endogenous TGF-b reduces expression of CTGF
and type I procollagen in primary adult human dermal fibroblasts.
Fibroblasts were cultured in the presence of the indicated amounts of pan
TGF-b neutralizing antibody for 24 hours. (a) CTGF and (b) type I procollagen
mRNA were quantified by real-time reverse transcriptase (RT)-PCR. 36B4
mRNA levels were used as internal reference. Data are means±SEM, N¼ 3,
*Po0.05. (c) Fibroblasts were cultured in the presence of the indicated
amounts of pan TGF-b neutralizing antibody for the indicated times. Type I
procollagen protein secreted into the culture media was quantified by ELISA.
Data are means±SEM, N¼3, *Po0.05.
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mediates, at least in part, autocrine TGF-b-dependent type I
procollagen production in human dermal fibroblasts.
Type I (a2) procollagen (COL-1A2) promoter activity is
regulated by CTGF in human skin fibroblasts
As knockdown of CTGF reduces type I procollagen mRNA
level, we next investigated whether CTGF is able to regulate
type I procollagen gene promoter activity. COL-1A2 promo-
ter/reporter construct was co-transfected with CTGF siRNA or
CTGF expression vector. As shown in Figure 7e, knockdown
of CTGF significantly attenuated COL-1A2 promoter activity.
In contrast, overexpression of CTGF significantly potentiated
COL-1A2 promoter activity.
CTGF regulation of type I procollagen expression is dependent
on TGF-b/Smad-signaling pathway in human skin fibroblasts
The above data indicate that CTGF functions as endogenous
regulator of autocrine TGF-b-dependent type I procollagen
production in human skin fibroblasts. However, molecular
mechanism(s) by which CTGF regulates type I procollagen
are largely unknown. We first determined whether CTGF
regulation of type I procollagen expression is dependent on
TGF-b-signaling pathway. We employed three approaches to
address this question. First, control and CTGF overexpressing
fibroblasts were treated with specific TGF-b type I receptor
kinase inhibitor SB431542 or vehicle. As shown in Figure 8a,
CTGF overexpression increased type I procollagen expres-
sion, and this increase was completely abolished by
SB431542. CTGF overexpression did not alter gene expres-
sion levels of TGF-b1, 2, or 3 (data not shown). These data
indicate that TGF-b receptor activity is required for CTGF-
mediated stimulation of type I procollagen in human skin
fibroblasts. To further substantiate this conclusion, we
simultaneously overexpressed CTGF and knocked down
Smad4, or overexpressed inhibitory Smad7. Induction of
type I procollagen by CTGF overexpression was completely
blocked by either the knockdown of Smad4 or overexpression
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Figure 5. Knockdown of endogenous TGF-bs reduces expression of CTGF
and type I procollagen in primary adult human dermal fibroblasts. (a)
Fibroblasts were transfected with the indicated non-specific (Ctrl) or TGF-b
isoform-specific siRNA. TGF-b1, TGF-b2, and TGF-b3 mRNA levels were
determined by real-time reverse transcriptase (RT)-PCR, 48 hours after
transfection. 36B4 mRNA levels were used as internal reference. Data are
means±SEM, N¼ 3, *Po0.05. (b–e) Fibroblasts were transfected with pooled
TGF-b1, TGF-b2, and TGF-b3 siRNA. Cells were harvested 48 hours after
transfection and analyzed for CTGF or type I procollagen mRNA or protein
levels. Transcript levels were determined by real-time RT-PCR (36B4 mRNA
was used as internal reference), and protein levels were determined by
western analyses (b-actin was used as internal control). (b) CTGF mRNA
levels. Data are means±SEM, N¼ 3, *Po0.05. (c) CTGF protein levels. Insets
show representative western blots. Data are means±SEM, N¼ 3, *Po0.05.
(d) Type I procollagen mRNA levels. Data are means±SEM, N¼3, *Po0.05.
(e) Type I procollagen protein levels. Insets show representative western blots.
Data are means±SEM, N¼3, *Po0.05.
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Figure 6. Inhibition of type I TGF-b receptor reduces expression of CTGF
and type I procollagen in primary adult human dermal fibroblasts.
Fibroblasts were treated with DMSO vehicle (Ctrl) or type I TGF-b receptor
inhibitor SB431542 (10 mM) for 24 hours. CTGF and type I procollagen mRNA
and protein levels were determined by real-time reverse transcriptase
(RT)-PCR and western analyses, respectively. (a) CTGF mRNA levels were
normalized to 36B4 mRNA levels, used as internal reference. Data are
means±SEM, N¼ 3, *Po0.05. (b) CTGF protein levels were normalized to
b-actin used as internal control. Insets show representative western blots.
Data are means±SEM, N¼ 3, *Po0.05. (c) Type I procollagen mRNA levels
were normalized to 36B4 mRNA levels, used as internal reference. Data are
means±SEM, N¼ 3, *Po0.05. (d) Type I procollagen protein levels were
normalized to b-actin used as internal control. Insets show representative
western blots. Data are means±SEM, N¼ 3, *Po0.05.
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of Smad7 (Figure 8b). These data further show that the ability
of CTGF to augment TGF-b induction of type I procollagen
expression is dependent on intact TGF-b-signaling pathway.
CTGF regulation of type I procollagen expression is not
mediated through direct activation of TGF-b/Smad-signaling
pathway in human skin fibroblasts
It has recently been reported that CTGF potentiates the
binding of TGF-b to its receptor complex, thereby stimulating
Smad2 phosphorylation and Smad-dependent transcriptional
activity, in mink lung epithelial cells (Abreu et al., 2002).
Therefore, we examined whether similar mechanisms operate
in human dermal fibroblasts, under conditions we deter-
mined in which CTGF knockdown or overexpression
regulated type I procollagen expression. Interestingly, CTGF
knockdown did not alter Smad2 or Smad3 phosphorylation
(Figure 9a). Similarly, CTGF overexpression did not alter
either Smad2 or Smad3 phosphorylation (Figure 9a). Con-
sistent with these results, CTGF knockdown or overexpres-
sion had no effect on transcription of TGF-b/Smad3-
dependent reporter gene (Figure 9b). These data argue
against CTGF acting to regulate type I procollagen expression
through direct augmentation of the TGF-b/Smad-signaling
pathway.
DISCUSSION
Type I collagen is the major structural protein in human skin.
Age-dependent collagen loss causes elderly skin to become
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primary adult human dermal fibroblasts. Fibroblasts were transfected with
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levels were quantified by western analyses. Insets show representative
western blots. Data are means±SEM, N¼ 3, *Po0.05. (b) Fibroblasts were
transfected with empty vector () (pCDNA3.1) and non-specific siRNA (Ctrl
siRNA), or CTGF expression vector with Smad4 siRNA, or Smad7 expression
vector. Whole cell protein extracts were prepared 48 hours after transfection.
Type I procollagen, CTGF, Smad4, Smad7, and b-actin (internal reference)
protein levels were quantified by western analyses. Insets show representative
western blots. Data are means±SEM, N¼ 3, *Po0.05.
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thin and fragile. In this study, we investigated the role of
TGF-b/Smad pathway and CTGF in age-dependent reduction
of collagen production in human skin. Our results show
significant decrease of TGF-b1 and CTGF in fibroblasts in
aged human skin in vivo, and type I procollagen production
by human dermal fibroblasts is dependent on both TGF-b
and CTGF.
We find that expression levels of TGF-b1, CTGF, or type I
procollagen do not significantly differ between dermal
fibroblasts cultured from aged or young skin (unpublished
data). These data highlight the importance of factors within
the tissue environment, rather than inherent genetic or
epigenetic alterations, as key determinants of downregulation
of the TGF-b/Smad/CTGF/procollagen axis in aged human
skin. We have previously described increased fragmentation
of the collagenous ECM and attendant reduction of fibroblast
stretch in aged human skin (Fisher et al., 2002, 2009; Varani
et al., 2006). Decreased mechanical tension is known to
reduce collagen production by skin fibroblasts (Fligiel et al.,
2003; Varani et al., 2006; Fisher et al., 2008). Thus, age-
dependent decline of the TGF-b/Smad/CTGF/procollagen
axis in human skin may originate from altered structural
and mechanical properties of the dermal ECM. Molecular
mechanisms that sense mechanical tension and couple it to
cellular processes, such as collagen production, are not well
understood. Interestingly, we have observed that reduced
mechanical tension impairs the TGF-b/Smad pathway in
human skin fibroblasts (Quan TH and Fisher GJ, unpublished
observation). These data suggest that TGF-b signaling may be
regulated in part by mechanosensing mechanisms.
CTGF was originally isolated from cultured endothelial
cells and later reported to be highly expressed in fibrotic
disorders (Bradham et al., 1991; Frazier et al., 1996;
Grotendorst et al., 1996; Grotendorst, 1997; Abraham
et al., 2000; Leask and Abraham, 2003, 2004). Here, we
provide evidence that CTGF functions as an intrinsic,
physiological mediator of type I procollagen expression,
and that reduced expression of CTGF contributes to age-
dependent reduction of type I procollagen production
observed in human skin. We find that reduced expression
of CTGF in dermal fibroblasts in aged human skin in vivo
mirrors reduced expression of type I procollagen. These data
are in agreement with our previous report that CTGF is
constitutively expressed in normal human skin in vivo (Quan
et al., 2002b). CTGF knockdown and overexpression results
in reduced and increased expression, respectively, of type I
procollagen in human dermal fibroblasts. This regulation of
type I procollagen production by CTGF is mediated, at least
in part, by transcriptional mechanisms.
It is well documented that CTGF is rapidly and potently
induced by TGF-b in a variety of cells including primary
human skin fibroblasts (Quan et al., 2002b). Synergy between
CTGF and TGF-b has been reported in a mouse fibrosis model
(Mori et al., 1999). Injection of TGF-b or CTGF alone into
mouse skin caused transient fibrotic tissue formation. How-
ever, simultaneous injection of TGF-b plus CTGF produced
long-term, persistent fibrotic tissue formation. Consistent with
these data, recently Chujo et al. (2005) reported that serial
subcutaneous injection of CTGF after TGF-b resulted in a
significant increase of COL1A2 (type I (a2) procollagen 1A2)
promoter activity and mRNA expression compared with
TGF-b treatment alone. CTGF has also been shown to induce
COL1A2 promoter activity in proximal tubular epithelial cells
(Gore-Hyer et al., 2002). Furthermore, Yang et al. (2004)
showed that CTGF augments TGF-b-induced myofibroblast
differentiation in normal rat kidney fibroblasts in vitro.
The CTGF has been reported to directly bind TGF-b1 and
increase the interaction of TGF-b with its receptors in non-
fibroblast cell lines (Abreu et al., 2002). This enhancement of
TGF-b binding led to increased Smad phosphorylation and
Smad-dependent transcriptional activity. These effects of
exogenous CTGF were observed only at sub-nanomolar
TGF-b concentrations (p10 pM). In our studies, under
conditions in which overexpression or knockdown of CTGF
substantially altered type I procollagen expression, there
were no significant effects of either overexpression or
knockdown of CTGF on TGF-b-dependent Smad2/3 phos-
phorylation or Smad3 transcriptional activity. These data
indicate that the ability of endogenous CTGF to regulate
type I procollagen expression is not dependent on direct
potentiation of Smad activation in human dermal fibroblasts.
––
–––
–
–
–
–
–
+
+
+
+
+ +
CTGF siRNA
SBEX4
CTRL
CTGF vector
0
100
200
300
400
500
TG
F-
β r
e
po
rte
r a
ct
iv
ity
(A
rbi
tra
ry
 u
ni
t)
β-Actin
CTGF
Total Smad 3
Total Smad 2
p-Smad 3
p-Smad 2
Sm
ad
 2
/3
 P
ho
sp
ho
ry
la
tio
n
(Fo
ld
 c
ha
ng
e)
0.0
0.5
1.0
1.5
2.0 p-Smad2
p-Smad3
CTRL
CT
RL
CTGF
siRNA
CT
GF
siR
NA
CTGF
vector
CT
GF
ve
cto
r
a
b
Figure 9. CTGF does not modulate TGF-b/Smad-signaling pathway in
primary adult human dermal fibroblasts. (a) Fibroblasts were transfected with
CTGF siRNA or CTGF expression vector or their appropriate controls (CTRL),
non-specific siRNA, or empty vector pCDNA3.1. Whole cell lysates were
prepared 48 hours after transfection. Phosphorylated Smad2 (p-Smad2),
phosphorylated Smad3 (p-Smad3), total Smad2, total Smad3, CTGF, and
b-actin (internal reference for normalization) protein levels were determined
by western analyses. Insets show representative western blots. N¼3.
(b) Fibroblasts were co-transfected with Smad3 luciferase reporter construct
(SBEX4) and LacZ reporter (internal control for normalization), or CTGF
siRNA, or CTGF expression vector, or their appropriate controls (CTRL),
empty luciferase reporter plasmid (pGL3), or non-specific siRNA, or empty
expression vector. Whole cell extracts were prepared 48 hours after
transfection, and assayed for luciferase and b-galactosidase activities. Data
are means±SEM, N¼3.
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Shi-Wen et al. (2006) have reported that CTGF action is Smad
independent.
We found that the ability of CTGF to upregulate type I
procollagen is dependent on intact TGF-b signaling. Re-
cently, Qi et al. (2005) reported that the profibrotic effect of
CTGF was completely abrogated in the presence of pan-
specific TGF-b and TGF-b type II receptor neutralizing
antibodies in renal cortical fibroblasts, indicating that CTGF
requires intact TGF-b signaling to exert its effect on ECM
production. CTGF is potently induced by TGF-b and this
increased CTGF stimulates type I procollagen expression.
Thus, CTGF is both regulated by TGF-b signaling, and is
required for downstream action of TGF-b.
The mechanism by which CTGF exerts is regulatory effects
on TGF-b-dependent type I collagen production is not
known. Emerging evidence indicates that the actions of
CTGF, at least in part, are mediated through its interactions
with integrins, which bind to ECM proteins. CTGF has been
shown to bind to a variety of integrins including a5b1
(Nishida et al., 2007), avb3 (Babic et al., 1999), a6b1 (Heng
et al., 2006); (Chen et al., 2001b), a4b1 (Chen et al., 2004),
aMb2 (Schober et al., 2002), and aIIbb3 (Jedsadayanmata
et al., 1999), in a cell type-specific manner. This binding
can activate integrin-signaling pathways leading to activation
of focal adhesion kinase and MAP kinases. CTGF has
also been reported to bind to ECM heparin sulfate proteogly-
cans perlecan (Nishida et al., 2003) and syndecan 4
(Chen et al., 2004). These data support the concept that
CTGF cooperates with ECM proteins to specify functional
interactions with their cell surface receptors (Yeger and
Perbal, 2007).
The TGF-b is the most potent stimulator of CTGF gene
expression (Holmes et al., 2001; Leask et al., 2003).
Therefore, reduced expression of TGF-b1 in aged human
skin is likely a major contributing factor to the observed
reduction of CTGF. We have previously reported that UV
irradiation downregulates type II TGF-b receptor and thereby
substantially reduces cellular responsiveness to TGF-b (Quan
et al., 2001). Interestingly, type II TGF-b receptor expression
is reduced in dermal fibroblasts in aged human skin in vivo
(Quan et al., 2006). These data indicate that downregulation
of type II TGF-b receptor may also contribute to reduced
expression of CTGF in aged human skin. In addition, it has
been shown that c-Jun NH2-terminal kinase/c-Jun/mitogen-
activated protein kinase (JNK/c-Jun/MAPK) pathway antag-
onizes TGF-b induction of CTGF transcription (Leivonen
et al., 2001; Leask et al., 2003). We have previously reported
that JNK/c-Jun/MAPK pathway is increased in aged compared
with that in young human skin in vivo (Chung et al., 2000),
suggesting that alterations of JNK/c-Jun/MAPK pathway may
contribute to reduced expression of CTGF in aged human
skin. c-Jun directly interacts with activated Smad proteins in
the nucleus to prevent their binding to target genes
(Verrecchia et al., 2000). c-Jun also competes with Smad
proteins for the common transcription co-activator p300.
Both mechanisms can simultaneously contribute to the c-Jun-
mediated inhibition of TGF-b/Smad-signaling pathway.
Therefore, elevated c-Jun may impair TGF-b/Smad signaling,
which may in turn contribute to reduced expression of CTGF
observed in aged human skin.
In summary, data presented above show that TGF-b1 and
CTGF are significantly reduced in aged human skin in vivo.
Given the pivotal, synergistic role of endogenous TGF-b and
CTGF in regulating type I procollagen synthesis by dermal
adult human fibroblasts, it is likely that reduced expression of
these two profibrotic cytokines is the key to reduced
production of type I procollagen, which is a prominent
feature of aged human skin.
METHODS AND MATERIALS
Materials
Dulbecco’s Modified Eagle’s Media (DMEM), fetal bovine serum,
trypsin solution, penicillin, and streptomycin were purchased from
Invitrogen Life Technology (Carlsbad, CA). CTGF antibody was
purchased from Santa Cruz Biotechnology (Santa Cruz, CA); type I
procollagen antibody used for western blot was purchased from RDI
Research Diagnostics (Flanders, NJ); rat type I procollagen anti-
body (Millipore, Burlington, MA) was used for immunohistology;
phospho-Smad2 and phospho-Smad3 antibodies were purchased
from Cell Signaling Technology (Beverly, MA); total Smad2 and
Smad3 antibodies were purchased from Santa Cruz Biotechnology;
human recombinant TGF-b1 was purchased from R&D Systems
(Minneapolis, MN). Unless otherwise stated, all other reagents were
purchased from Sigma Chemical Company (St Louis, MO).
Procurement of human tissue samples
Human skin samples were obtained from adult volunteers, as
previously described (Fisher et al., 1991a, 1997, 1998). Individuals
were grouped according to age as follows: 21–30 years for young
group and X80 years for aged group. Full-thickness skin punch
biopsies (4mm) were obtained from sun-protected buttock skin. All
procedures involving human individuals were approved by the
University of Michigan Institutional Review Board, and all indivi-
duals provided written informed consent in adherence to the
Declaration of Helsinki Principles.
Cell culture
Primary human skin fibroblasts were cultured from punch biopsies of
adult normal buttock skin (aged 21–55 years), as described
previously (Fisher et al., 1991b). Cells were cultivated in DMEM
supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad,
CA). Cells were plated at 70–80% confluence, and used 1 day later.
Cells were used between passages 3 and 7. Independent replicates of
studies, indicated by N number in figure legends, were performed
with cells from different individuals.
RNA isolation, laser capture microdissection, and quantitative
real-time reverse transcriptase PCR
Dermis was separated from epidermis by dissection, and total RNA
was extracted from human skin dermis using commercial kit
(RNeasy Midi Kit, Qiagen, Chatsworth, CA) as previously described
(Quan et al., 2002b; Fisher et al., 2009) and described in
Supplementary Material. Fibroblasts (approximately 200 cells) from
frozen skin sections, from six young (21–30 years) and six aged (X80
years) individuals were obtained by laser capture microdissection
using a Leica AS LMD (Leica Microsystems, Wetzlar, Germany), as
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previously described (Quan et al., 2002b, 2004, 2006). Quantitative
real-time reverse transcriptase PCR, and PCR primer and probe
sequences have been previously described (Quan et al., 2002b,
2004, 2006) or are described in Supplementary Table 1.
In situ hybridization
RNA probes were prepared from cDNA of TGF-b1 (Quan et al.,
2002a), type I(a1) procollagen (Fisher et al., 2000), and CTGF
(generously provided by Dr Grotendorst, Department of Cell Biology
and Anatomy, University of Miami School of Medicine, Miami, FL).
Digoxigenin-containing sense and antisense riboprobes were
synthesized using T7 and SP6 ribonucleic polymerase, respectively.
Frozen skin sections (5mm) were mounted, fixed, treated, and
hybridized as previously described (Fisher et al., 1997; Quan et al.,
2002b). Hybridization signals were detected immunohistochemically
by alkaline phosphatase-conjugated anti-digoxigenin antibody. The
sense riboprobe yielded minimal background signal (data not shown).
Immunohistology
Detection of type I procollagen, TGF-b1, and CTGF in young and
aged human skin by immunohistology was performed as previously
described (Quan et al., 2001, 2002b, 2005, 2006) and described in
Supplementary Material.
Western analysis and type I procollagen ELISA
Western analyses and type I procollagen ELISA were performed as
previously described (Quan et al., 2002b, 2004, 2005) and
described in Supplementary Material.
Transfection
Oligonucletide siRNA sequences targeting CTGF, TGF-b1, b2, and
b3 were designed from human mRNA open reading frames
according to OligoEngine (Seattle, WA) website instructions and
submitted to a BLAST search against human genome database to
confirm specificity (see Supplementary Material for sequences,
Table II). siRNA oligonucleotides were synthesized by Qiagen.
CTGF expression vector (CTGF-V5 TOPO) (Wahab et al., 2001) was
generously provided by Dr Wahab (Cell and Molecular Biology
Section, Imperial College School of Medicine, London). TGFb/Smad
reporter construct (p3TP-Lux) was generously provided by Dr Joan
Massague (Sloan-Kettering Institute, New York, NY). Human skin
fibroblasts were transiently transfected by electroporation using
Amaxa Nucleofector (Amaxa, Koeln, Germany). After transfection
(48 hours), total RNA and cellular protein were extracted, and mRNA
and protein levels were determined by real-time reverse transcrip-
tase PCR and western analysis, respectively, as described above.
Luciferase activity was measured using an enhanced luciferase assay
kit (PharMingen International, San Diego, CA) according to the
manufacturer’s protocol. COL1A2 CAT reporter gene plasmid
(772ti þ 58) was provided by Dr Trojanowski (Ihn et al., 1997).
CAT assays were carried out as previously described (Quan and
Fisher, 1999; Quan et al., 2004). Aliquots containing identical
b-galactosidase activity were used for each luciferase assay.
Statistical analysis
Comparisons were made with the paired t-test (two groups) or the
repeated measures of ANOVA (more than two groups). Multiple
pair-wise comparisons were made with the Tukey Studentized
Range test. All P-values are two-tailed and considered significant
when o0.05.
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